Computational Biology and Bioengineering

Companies building the computational infrastructure that modern biomedical research requires to function.

Biological systems produce immense quantities of information through genomic sequencing, clinical research, and laboratory experimentation. Standard experimental biology cannot process this information at the speed or scale required to capitalize on its potential. Computational platforms that translate biological data into actionable research hypotheses are becoming indispensable infrastructure for pharmaceutical companies, research institutions, and clinical organizations. The companies we invest in do not simply study data. They narrow the search space for viable therapies and accelerate the pace of scientific discovery in ways that were not possible a decade ago.

The integration of computational methods into life sciences represents one of the most consequential shifts in modern medicine. The cost of genomic sequencing has declined by several orders of magnitude, producing datasets of rare scale. Computational platforms that can spot patterns invisible to standard experimental approaches are not optional tools. They are becoming the operating infrastructure of biomedical research. We view companies building this infrastructure as central participants in the next phase of biomedical innovation. The structural advantage compounds: the more data a platform processes, the more accurate its models become, and the harder it is for competitors to replicate the built up insight.